Lupron Depot-6 Month 45mg

Initial worsening of signs/symptoms (eg, bone pain, neuropathy, hematuria, or bladder outlet obstruction) may occur during the first few weeks. Monitor for tumor flare symptoms. Patients with metastatic vertebral lesions and/or urinary tract obstruction; monitor closely for new/worsening symptoms. Monitor serum testosterone, PSA. Metabolic syndrome (hyperglycemia, diabetes, hyperlipidemia). Increased risk of MI, sudden cardiac death, stroke. Monitor serum lipids, blood glucose, HbA1c, and for signs/symptoms of CVD during therapy. Increased risk of convulsions in those with history of seizures, epilepsy, cerebrovascular disorder, CNS anomalies or tumors. Risk for QT prolongation in those with congenital long QT syndrome, electrolyte abnormalities (correct and monitor), or CHF; consider monitoring ECGs. Monitor for severe cutaneous adverse reactions (including SJS/TEN, DRESS, AGEP); interrupt if suspected and permanently discontinue if confirmed or for other Grade 4 skin reactions. Instruct patient on correct self administration. Embryo-fetal toxicity. Pregnancy. Nursing mothers: not recommended.